Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant versus flecainide for atrial contractility after pharmacological cardioversion of atrial fibrillation
NL-OMON37797Phase 4Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vernakalant and flecainide in Atrial fibrillation (AFib) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Atrial contractility after conversion to sinus rhythm. Planned start Aug 2012; status: not yet recruiting.
02
Drugs
vernakalantflecainide
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON37797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37797.